Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Febrile Neutropenia 6Neutropenia 5Neoplasms 4Infections 4Fever 4Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Tract Infections 1Stomach Neoplasms 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Arterial Hypertension 1Pseudomonas Infections 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1

Interventions

Gemcitabine 683130-nm albumin-bound paclitaxel 198Fluorouracil 188Oxaliplatin 175Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 131Irinotecan 112Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 72Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 50Cyclophosphamide 49folfirinox 45Specimen Handling 42Docetaxel 42Cetuximab 40irinotecan sucrosofate 38Biopsy 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Vancomycin × Clear all
NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
22 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡